7th Status Seminar on Chemical Biology

5. - 6. Dezember 2011 Frankfurt am Main


On-line registration is closed.




 The organizing committee cordially invites you to the 7th Status Seminar on Chemical Biology. 
The conference will again present cutting-edge research at the prolific interface of chemistry and biology. This year´s topics are chemical systems biology and biologically active peptides.

Monday, December 5th 2011
Tuesday, December 6th 2011



DECEMBER 5th, 2011
Room: Carls-Duisberg



13:00 KEYNOTE: The dynamic Ras cycle
  H. Waldmann, Max-Planck-Institut, Dortmund/D
13:40 Design of potent LRRK2 leads and elucidation of mechanism of action of novel anti-leukaemia compounds by quantitative proteomics
  C. Hopf, J. Perrin, A. Dittmann, M. Bantscheff, G. Drewes, Cellzome AG, Heidelberg/D
14:00 Towards a mechanistic understanding of cell transitions, and chemotherapy response using differential analysis of high-throughput data in a network
  G. Fuellen, University of Rostock/D
14:20 Combining automatic active site analysis and docking for structure-based protein function prediction.
  A. Volkamer, T. Watolla, University of Hamburg/D; F. Sonnenburg, C. Lemmen, BioSolveIT GmbH, Bonn/D; D. Kuhn, F. Rippmann, Merck Serono, Darmstadt/D; M. Rarey, University of Hamburg/D
14:40 Combining virtual and biological screening for efficient lead structure identification of epigenetic targets
  W. Sippl, Universität Halle-Wittenberg/D


Coffee break

15:30 KEYNOTE: Network pharmacology: how drug design can learn the lessons from system biology

A. Hopkins, University of Dundee/UK









"Synthesis of scorpion shaped glycogen synthase kinase-3 inhibitors" presented by F. Lo Monte, TU Darmstadt/D

"Chemical biology to dissect and target the degradome of Taspase1" presented by C. Bier,  University Medical Center Mainz/D

"Novel inhibitors of essential viral protein-protein interactions identified by PCA in vitro" presented by H. Eickhoff, EMC microcollections GmbH, Tübingen/D

"Targeting a protein-protein interface in M. tuberculosis: first thioredoxin reductase inhibitors with high bioactivity" presented by R.J. Marhöfer, Intervet Innovation GmbH, Schwabenheim/D

"ß-Lactones as a new class of anti-virulence drugs" presented by V. Korotkov, Ludwig-Maximilians-Universität München, Garching/D

"Development of homogeneous proximity assays for JMJD2A/2C histone demethylases" presented by M. Lässle, PerkinElmer, Rodgau/D

16:40 KEYNOTE: From protein-chemical interaction networks to human phenotypes

M. Kuhn, Biotec-TU Dresden/D


Presentation of candidates


Buffet and Poster Session



General assembly of the "Fachgruppe Chemische Biologie"


                       DECEMBER 6th, 2011
Room: Carls-Duisberg
09:00 KEYNOTE: Peptide drugs - State of the art and innovative applications
  A. Beck-Sickinger, University of Leipzig/D
09:40 Exploring host - Pathogen interactions using scaffolded and assembled peptides as protein binding site mimetics
  J. Eichler, A. Berthelmann, J. Meier, M. Mössl, K. Möbius, Universität Erlangen-Nürnberg/D
10:00 Biomimetic screening of class B G protein-coupled receptors
  C. Devigny, B. Hoogeland, C. Cuboni, F. Hausch, MPI of Psychiatry, Munich/D
10:20 A new LIM kinase inhibitor with anticancer activity, identified in a phenotype-based screen probing for microtubule stability
  R. Prudent, INSERM, Grenoble/F; E. Vassal, Grenoble/F; C.H. Nguyen, CNRS, Paris/F; S. Knapp, Oxford University/UK; O. Bernard, Melbourne University, Victoria/AUS; L. Lafanechère, CNRS, Grenoble/F
10:40 Goals in chemical systems biology: how synthetic chemistry and synthetic biology complement each other in creating & studying posttranslational protein lipidation pattern
  B. Maksimovic, C. Yao, N. Mathaiyan, S. Schiller, FRIAS, Freiburg/D


Coffee break

11:30 KEYNOTE: Discovery and applications of naturally occurring cyclic peptides in drug design

D. Craik, University of Queensland/AUS


New peptide natural products from entomopathogenic bacteria


C. Dauth, H. B. Bode, Universität Frankfurt/D

12:30 Identification of novel pTyr mimetics through a fragment based dynamic ligation (DLS) screening approach

V. Martos-Riaño, Leibniz-Institut für Molekulare Pharmakologie, Berlin/D; J. Rademann, Universität Leipzig/D


Substrate-selective inhibition of protein kinase PDK1 with small allosteric compounds


K. Busschots, L.A. Lopez-Garcia, C. Lammi, Universitätsklinikum Frankfurt/D; A. Stroba, University of Saarland, Saarbrücken/D; S. Zeuzem, A. Piiper, S. Neimanis, J. Arencibia, Universitätsklinikum Frankfurt/D; M. Engel, University of Saarland, Saarbrücken/D; J.O. Schulze, R.M. Biondi, Universitätsklinikum Frankfurt/D


End of the Seminar


Synthesis of scorpion shaped glycogen synthase kinase-3 inhibitors


F. Lo Monte, T. Kramer, TU Darmstadt/D; A. Fuertes, J.M. Dominguez, Noscira S.A. - Drug Discovery, Madrid/E; B. Plotkin, H. Eldar-Finkelman, Tel Aviv University/IL; B. Schmidt, TU Darmstadt/D


Peptide constructs that interfere with the Sec pathway can reduce the secretion of the pathogenicity factor V8 protease by S. aureus


J. Al-Qudsi, Helmholtz-Centre for Infection Research, Braunschweig/D; R. Frank, Helmholtz-Centre for Infection Research and Leibniz Institute for Molecular Pharmacology, Braunschweig and Berlin/D; W. Tegge, Helmholtz-Centre for Infection Research, Braunschweig/D


Chemical biology to dissect and target the degradome of Taspase1


C. Bier, University Medical Center Mainz/D; L. Kunst, University Duisburg-Essen/D; R. Stauber, University Medical Center Mainz/D; S. Knauer, University Duisburg-Essen/D


Bioactive peptides derived from potato proteins


I. Schoenbeck, S. Beutel, T. Scheper, Leibniz Universität Hannover/D


Novel inhibitors of essential viral protein-protein interactions identified by PCA in vitro


H. Eickhoff, EMC microcollections GmbH, Tübingen/D; F. Wagner, M. Schnee, U.H. Koszinowski, Z. Ruzsics, Max von Pettenkofer Institute, München/D; K.-H. Wiesmüller, EMC microcollections GmbH, Tübingen/D 


Peptide & protein based bioactive molecules and materials accessed via bionic chemistry


M.C. Huber, C. Hege, S.M. Schiller, FRIAS, Freiburg/D


Computational prediction of enzyme activity in different buffer solutions


K. Schomburg, University of Hamburg/D; I. Ardao, K. Götz, F. Rieckenberg, A. Liese, A.-P. Zeng, TU Hamburg-Harburg/D; M. Rarey, University of Hamburg/D


Efficient biotechnological production of a potent antimicrobial peptide


M. Felle, S. Jenewein, BASF SE, Ludwigshafen/D


Characterization of antiviral effects of inhibitors of the cytomegalovirus nuclear egress complex


F. Wagner, University of Munich/D; H. Eickhoff, EMC microcollections, Tübingn/D; L. Scrivano, M. Pogoda, University of Munich/D; K-H. Wiesmüller, EMC microcollections, Tübingen/D; U.H. Koszinowski, Z. Ruzsics, University of Munich/D


Vioprolid A: a potential new selective PI3Kß inhibitor


M. Fountain, Y. Muthukumar, R. Frank, F. Sasse, Helmholtz Centre for Infection Research, Braunschweig/D


Development of the first short and linear Urotensin II analogues with biased characteristics


S. Bandholtz, B. Wiedenmann, C. Grötzinger, Charité, Berlin/D


Site-specific covalent labelling of proteins in living cells


T. Plass, S. Milles, C. Koehler, C. Schultz, E. Lemke, EMBL Heidelberg/D


Searching for new trypanothione reductase inhibitors by combining in silico and in vitro screening technologies


M. Beig, F. Bender, O. Koch, F. Oellien, A. Rohwer, M. Gassel, Intervet Innovation GmbH, Schwabenheim/D; G. Unden, University of Mainz/D; R.L. Krauth-Siegel, University of Heidelberg/D; P.M. Selzer, Intervet Innovation GmbH, Schwabenheim/D

 LMP2 A new druggable binding site in trypanothione synthetase identified via an extensive computational analysis

O. Koch, Intervet Innovation GmbH, Schwabenheim/D; D. Cappel, M. Nocker, University of Würzburg/D; T. Jäger, L. Flohé, MOLISA GmbH, Magdeburg/D; C. Sotrifer, University of Würzburg/D; P.M. Selzer, Intervet Innovation GmbH, Schwabenheim/D

 LMP3 Targeting a protein-protein interface in M. tuberculosis: first thioredoxin reductase inhibitors with high bioactivity

O. Koch, Intervet Innovation GmbH, Schwabenheim/D; N. Doil, Medizinische Hochschule Hannover/D; F. Heller, F. Stuhlmann, S. Schmitt, D. Khandavalli, L. Schinzer, L. Flohé, MOLISA GmbH, Magdeburg/D; F.C. Bange, Medizinische Hochschule Hannover/D; T. Jäger, MOLISA GmbH, Magdeburg/D; R.J. Marhöfer, P.M. Selzer, Intervet Innovation GmbH, Schwabenheim/D

 LMP4 ß-Lactones as a new class of anti-virulence drugs

V. Korotkov, Ludwig-Maximilians-Universität München, Garching/D; E. Zeiler, TU München, Garching/D; K. Lorenz-Baath, T. Böttcher, Ludwig-Maximilians-Universität München, Garching/D; S. Sieber, TU München, Garching/D

 LMP5 EU-OPENSCREEN - A European infrastructure of open screening platforms for chemical biology

B. Stechmann, R. Frank, EU-OPENSCREEN / FMP Leibniz-Institut für Molekulare Pharmakologie, Berlin/D

 LMP6 Development of helix-mimetic scaffolds as potential disruptors of PKA-AKAP interactions

G. Schaefer, MDC Berlin, FMP Berlin, FU Berlin/D; J. Milic, MDC Berlin, FMP Berlin/D; C. Schillinger, P. Schmieder, G. Krause, FMP Berlin/D; W. Rosenthal, MDC Berlin/D; J. Rademann, University of Leipzig/D; E. Klussmann, MDC Berlin/D

 LMP7 Provision for enhanced reaction conditions under continuous flow: Eschenmoser coupling

S. Singh, A. Schober, G. A. Groß, TU Ilmenau/D

 LMP8 Drug-protein interactions probed by Capture Compound Mass Spectrometry (CCMS)

J.J. Fischer, S. Michaelis, C. Dalhoff, O.Y. Graebner, K. Bartho, A.K. Schrey, caprotec bioanalytics GmbH, Berlin/D; A. Diehl, Leibniz-Institut fuer Molekulare Pharmakologie, Berlin/D; F. Kroll, M. Sefkow, S. Baumgart, M. Glinski, H. Koester, M. Dreger, caprotec bioanalytics GmbH, Berlin/D

 LMP9 Development of homogeneous proximity assays for JMJD2A/2C histone demethylases

A. Rodenbrock, M. Roy, L. Pedro, N. Gauthier, A. Labonte, V. Paquet, PerkinElmer, Montreal/CDN; M. Lässle, PerkinElmer, Rodgau/D; L. Beaudet, R. Rodriguez-Suarez, PerkinElmer, Montreal/CDN

 LMP10 Thiol-tagged D-/L-peptides for dynamic covalent capture and informed antimicrobial peptide library design

K.B. Jadhav, FSU, Jena/D; R.J. Lichtenecker, B. Ellinger, H.-M. Han, A. Bullach, M. Grabenbauer, MPI-MP, Dortmund/D; H.-D. Arndt, FSU, Jena/D

 LMP11 Pharmacological inhibition of LIM kinase stabilizes microtubules and suppresses tumor growth

R. Prudent, INSERM, La Tronche/F

 LMP12 Targeting AKAP-PKA interactions with small molecules as a new concept for the treatment of heart failure

A. Eldahshan, J. Milic, K. Zülke, F. Goetz, Max Delbrück Center for Molecular Medicine, Berlin/D; J-P. von Kries, Forschungsinstitut für Molekulare Pharmakologie, Berlin/D; W. Rosenthal, E. Klussmann, Max Delbrück Center for Molecular Medicine, Berlin/D

 LMP13 Development of a tumour microenvironment mimicking 3D co-culture assay for drug discovery

E. Krausz, Janssen Research & Development, Beerse/B

 LMP14 From phenotype to mode of action: cellular impedance measurements for target discovery of bioactive compounds

R. Franke, T. Schneider, T. Schulze, F. Sasse, Helmholtz Centre for Infection Research GmbH, Braunschweig/D


-AG Tagungen-
-Daniela Sabolo-
Telefon: 069 / 75 64- 243
Telefax: 069 / 75 64- 176


Jetzt Mitglied werden